ScholarLens Back to search
2010•The Open Leukemia JournalOpen access

Management of Cytopenias During Treatment with Lenalidomide in Patients with Myelodysplastic Syndromes

Richard A. Wells

Open full text 0 citations

Abstract

Lenalidomide is approved for the treatment of Low and Intermediate-1 risk International Prognostic Scoring System categorized myelodysplastic syndromes (MDS) with deletion (del (5q)), and has an evolving role in other subtypes of MDS.Severe cytopenias may emerge with lenalidomide treatment, which appear to be related to elimination of the dysplastic clone.Although guidelines based on expert opinion have been published, the optimum management of lenalidomide-induced cytopenias in MDS in the "real world" setting is still evolving.We report two illustrative cases of lenalidomide-induced cytopenias in patients with del (5q) MDS, present an updated review of the literature and provide practical guidance for the management of cytopenias during lenalidomide treatment of MDS.

Open-access reader

About this research paper

What this paper is about

Lenalidomide is approved for the treatment of Low and Intermediate-1 risk International Prognostic Scoring System categorized myelodysplastic syndromes (MDS) with deletion (del (5q)), and has an evolving role in other subtypes of MDS.Severe cytopenias may emerge with lenalidomide treatment, which appear to be related to elimination of the dysplastic clone.Although guidelines based on expert opinion have been published, the optimum management of lenalidomide-induced cytopenias in MDS in the "real world" setting is still evolving.We report two illustrative cases of lenalidomide-induced cytopenias in patients with del (5q) MDS, present an updated review of the literature and provide practical guidance for the management of cytopenias during lenalidomide treatment of MDS.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Lenalidomide is approved for the treatment of Low and Intermediate-1 risk International Prognostic Scoring System categorized myelodysplastic syndromes (MDS) with deletion (del (5q)), and has an evolving role in other subtypes of MDS.Severe cytopenias may emerge with lenalidomide treatment, which appear to be related to elimination of the dysplastic clone.Although guidelines based on expert opinion have been published, the optimum management of lenalidomide-induced cytopenias in MDS in the "real world" setting is still evolving.We report two illustrative cases of lenalidomide-induced cytopenias in patients with del (5q) MDS, present an updated review of the literature and provide practical guidance for the management of cytopenias during lenalidomide treatment of MDS.

Key concepts: Lenalidomide, Myelodysplastic syndromes, Medicine, Cytopenia, Multiple myeloma, Thalidomide, International Prognostic Scoring System, Expert opinion

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Management of Cytopenias During Treatment with Lenalidomide in Patients with Myelodysplastic Syndromes — Research Paper | ScholarLens